Format

Send to

Choose Destination
Med Mal Infect. 2019 Feb;49(1):1-8. doi: 10.1016/j.medmal.2018.04.395. Epub 2018 May 20.

Chickenpox: An update.

Author information

1
Assistance publique-Hôpitaux de Marseille (AP-HM), pharmacie usage intérieur, hôpital Nord, Chemin-des-Bourrely, 13915 Marseille cedex 20, France; Laboratoire de pharmaco-chimie radicalaire, faculté de pharmacie, Aix-Marseille Université, CNRS, ICR, UMR 7273, 27, boulevard Jean-Moulin-CS30064, 13385 Marseille cedex 05, France. Electronic address: coralie.lopresti@ch-edouard-toulouse.fr.
2
Assistance publique-Hôpitaux de Marseille (AP-HM), service central de la qualité et de l'information pharmaceutiques (SCQIP), hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France; Laboratoire de pharmaco-chimie radicalaire, faculté de pharmacie, Aix-Marseille Université, CNRS, ICR, UMR 7273, 27, boulevard Jean-Moulin-CS30064, 13385 Marseille cedex 05, France. Electronic address: christophe.curti@univ-amu.fr.
3
Assistance publique-Hôpitaux de Marseille (AP-HM), pharmacie usage intérieur, hôpital Nord, Chemin-des-Bourrely, 13915 Marseille cedex 20, France; Laboratoire de pharmaco-chimie radicalaire, faculté de pharmacie, Aix-Marseille Université, CNRS, ICR, UMR 7273, 27, boulevard Jean-Moulin-CS30064, 13385 Marseille cedex 05, France. Electronic address: marc.montana@ap-hm.fr.
4
Assistance publique-Hôpitaux de Marseille (AP-HM), pharmacie usage intérieur, hôpital de la conception, 147, boulevard Baille, 13005 Marseille, France; Laboratoire de pharmaco-chimie radicalaire, faculté de pharmacie, Aix-Marseille Université, CNRS, ICR, UMR 7273, 27, boulevard Jean-Moulin-CS30064, 13385 Marseille cedex 05, France. Electronic address: charles-eric.bornet@ap-hm.fr.
5
Assistance publique-Hôpitaux de Marseille (AP-HM), pharmacie usage intérieur, hôpital de la conception, 147, boulevard Baille, 13005 Marseille, France; Laboratoire de pharmaco-chimie radicalaire, faculté de pharmacie, Aix-Marseille Université, CNRS, ICR, UMR 7273, 27, boulevard Jean-Moulin-CS30064, 13385 Marseille cedex 05, France. Electronic address: patrice.vanelle@ap-hm.fr.

Abstract

Despite its benign characteristics, chickenpox is a childhood disease responsible for complications and deaths, particularly in the high-risk population. VariZIG®, not commercialized in France, is a good alternative for seronegative individuals exposed to the virus and not eligible for vaccination. The efficacy of routine vaccination has been demonstrated with a decrease in chickenpox incidence and with the development of herd immunity. Over time, the protective antibody titer of vaccinated people decreases and can be maintained by two doses of the vaccine. A tetravalent measles-mumps-rubella-chickenpox vaccine, used in the United States, has a good tolerability in spite of the occurrence of fever and febrile seizures. Routine vaccination would contribute to make savings in France, by reducing direct and indirect costs of chickenpox.

KEYWORDS:

Chickenpox; Vaccination; Varicelle

PMID:
29789159
DOI:
10.1016/j.medmal.2018.04.395
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center